Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors

Current Use of and Trends in Hematopoietic Cell Transplantation in the United States

(2020) Anita D'Souza et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

(2019) Javier Bolaños-Meade et al.   Lancet Haematology

Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial

(2019) Brenda M Sandmaier et al.   Lancet Haematology

Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

(2018) Stefan O. Ciurea et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell–Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide

(2017) Asad Bashey et al.   JOURNAL OF CLINICAL ONCOLOGY

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

(2017) Bart L. Scott et al.   JOURNAL OF CLINICAL ONCOLOGY

Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant

(2016) Y Wang et al.   LEUKEMIA

T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes

(2015) R Devillier et al.   BONE MARROW TRANSPLANTATION

Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults

(2015) Yvette L. Kasamon et al.   JOURNAL OF CLINICAL ONCOLOGY

HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM

(2015) M Robin et al.   LEUKEMIA

Incidence and Burden of the Myelodysplastic Syndromes

(2015) Christopher R. Cogle   Current Hematologic Malignancy Reports

HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry

(2014) Loren Gragert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)

(2013) W. Saber et al.   BLOOD

Graft failure in the modern era of allogeneic hematopoietic SCT

(2012) R Olsson et al.   BONE MARROW TRANSPLANTATION

SAS macros for estimation of direct adjusted cumulative incidence curves under proportional subdistribution hazards models

(2010) Xu Zhang et al.   COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE

Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome

(2010) Brian L. McClune et al.   JOURNAL OF CLINICAL ONCOLOGY

Defining the Intensity of Conditioning Regimens: Working Definitions

(2009) Andrea Bacigalupo et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Allogeneic Hematopoietic Stem-Cell Transplantation for Patients 50 Years or Older With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia

(2009) ZiYi Lim et al.   JOURNAL OF CLINICAL ONCOLOGY